Rezolute (NASDAQ:RZLT) Shares Cross Below 200 Day Moving Average - Time to Sell?

Rezolute logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rezolute shares dipped below their 200-day moving average of $3.94, falling as low as $3.86 before last trading at $3.92.
  • Analyst sentiment remains broadly positive: 12 analysts rate the stock Buy, one Hold and one Sell, for a Moderate Buy consensus and an average price target of $11.67.
  • Rezolute reported a quarterly loss of $0.18 per share, slightly better than the $0.19 loss analysts expected. The clinical-stage biotech is developing treatments for rare diseases, including a candidate for congenital hyperinsulinism.
  • MarketBeat previews the top five stocks to own by December 1st.

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $3.94 and traded as low as $3.86. Rezolute shares last traded at $3.92, with a volume of 2,474,500 shares changing hands.

Analyst Ratings Changes

A number of research firms have recently commented on RZLT. Weiss Ratings restated a "sell (d-)" rating on shares of Rezolute in a research report on Thursday, October 15th. Citigroup reaffirmed a "market outperform" rating on shares of Rezolute in a research note on Thursday, October 15th. Cantor Fitzgerald upgraded Rezolute from a "neutral" rating to an "overweight" rating in a research note on Monday, October 5th. Wedbush boosted their target price on Rezolute from $6.00 to $10.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Citizens Jmp boosted their price target on Rezolute from $11.00 to $15.00 and gave the company a "market outperform" rating in a report on Tuesday, October 6th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Rezolute presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Read Our Latest Stock Report on RZLT

Rezolute Stock Performance

The business's fifty day moving average price is $4.04 and its two-hundred day moving average price is $3.94. The firm has a market capitalization of $379.18 million, a P/E ratio of -5.16 and a beta of 0.65.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Sell-side analysts predict that Rezolute, Inc. will post -0.66 earnings per share for the current year.

Institutional Trading of Rezolute

Large investors have recently made changes to their positions in the company. Siren L.L.C. purchased a new position in shares of Rezolute in the first quarter worth about $10,151,000. Dimensional Fund Advisors LP grew its position in Rezolute by 273.7% in the first quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock worth $1,617,000 after acquiring an additional 388,346 shares during the period. Bank of New York Mellon Corp purchased a new stake in Rezolute in the 2nd quarter valued at about $1,104,000. Renaissance Technologies LLC raised its stake in shares of Rezolute by 72.4% in the 1st quarter. Renaissance Technologies LLC now owns 157,711 shares of the company's stock valued at $481,000 after acquiring an additional 66,250 shares during the period. Finally, Sei Investments Co. raised its position in Rezolute by 286.8% in the first quarter. Sei Investments Co. now owns 146,576 shares of the company's stock valued at $447,000 after purchasing an additional 108,679 shares during the period. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company's lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rezolute Right Now?

Before you consider Rezolute, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.

While Rezolute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines